#USA #Milford #Waters Corporation #Xevo TQ Absolute XR #Mass Spectrometer

Groundbreaking Launch of the Xevo TQ Absolute XR IVD Mass Spectrometer by Waters Corporation

On July 27, 2026, at the annual meeting of the Association for Diagnostics Laboratory Medicine (ADLM), Waters Corporation, traded under NYSE WAT, marked a significant advancement in clinical diagnostics with the introduction of the Xevo TQ Absolute XR IVD Mass Spectrometer. This sophisticated instrument brings together exceptional sensitivity and robustness, catering to a wide array of clinical applications including women's health, cancer diagnostics, and toxicology.

Unparalleled Sensitivity and Performance

The Xevo TQ Absolute XR stands out in the market as it offers up to five times greater sensitivity compared to competing instruments within its class. This state-of-the-art Technology enables detection of challenging analytes from smaller sample volumes, thereby elevating analytical performance significantly. The enhanced sensitivity is particularly critical in clinical settings that demand precise measurements at very low concentrations, such as those required for assessing estradiol levels in women's health and monitoring hormone-related cancers. In addition, it plays an essential role in toxicology, especially in distinguishing drugs of abuse through hair sample analysis.

Advancements in Analytical Consistency

With its innovative StepWave™ XR Ion Guide feature, the new IVD system provides a remarkable increase in robustness. This improvement allows for ion ratio consistency that is up to six times longer compared to its predecessor, the Xevo TQ Absolute, which translates into enhanced reliability for laboratories handling complex biological samples. These improvements enable labs to navigate the difficulties posed by various matrix components such as phospholipids and salts, ensuring laboratories maintain confidence in their analytical results.

Jianqing Bennett, Senior Vice President of Waters Advanced Diagnostics, emphasized the importance of this launch: "Waters’ IVD Systems provide clinical testing labs with the flexibility and precision necessary for clinicians to make informed decisions, especially when the accuracy of each test is critical. The Xevo TQ Absolute XR IVD System sets a new standard for sensitivity and robustness, promising a reduction in downtime and an increase in lab productivity."

Transforming Clinical Laboratory Operations

Cansford Laboratories’ Head of Laboratory Operations, James Nutt, remarked on the transformative impact of the new systems in their labs: "The Xevo TQ Absolute XR IVD Systems mark a pivotal improvement for us. This system amplifies our analytical reliability, broadens our substance testing capabilities, and enhances efficiency. With improved signal stability and sensitivity, we are now more confident than ever when analyzing close to decision cut-offs in complex matrices like human hair."

Together with the ACQUITY™ UPLC I-Class PLUS System, the Xevo TQ Absolute XR IVD Mass Spectrometer enables rapid and precise sample analysis, enhancing the overall performance of mass spectrometry. This integration not only bolsters sensitivity for challenging samples but also offers a user-friendly design aimed at maximizing laboratory uptime.

Availability and Future Prospects

The launch of the MassTrak LC-MS/MS IVD System, featuring the Xevo TQ Absolute XR, is now open for orders. As the clinical landscape continually evolves, the demand for highly sensitive and robust diagnostic tools grows. Waters Corporation is paving the way forward, equipping professionals in various fields with next-generation tools that improve patient outcomes and streamline laboratory processes.

In a world where precision in diagnostics can mean the difference between successful treatment and missed opportunities, the Xevo TQ Absolute XR IVD Mass Spectrometer from Waters Corporation showcases a commitment to excellence in scientific innovation. For more details on this groundbreaking technology, visit Waters' official site.